白三烯受体拮抗剂对吸烟哮喘患者病情控制的影响

目的：探讨白三烯受体拮抗剂对吸烟哮喘患者病情控制的影响。方法：选取2013年3-12月在门诊就诊的110例吸烟哮喘患者，按照随机数字表法将其分为对照组54例和观察组56例。对照组给予吸入糖皮质激素（布地奈德）治疗，必要时吸入β2受体激动剂；观察组在此治疗基础上加用孟鲁司特钠治疗，疗程4周。观察比较两组治疗前后哮喘控制测试（ACT）评分、哮喘症状评分、晨间及夜间呼气峰流速（PEF）。结果：观察组治疗后ACT评分、晨间及夜间PEF%pred均明显高于治疗前及对照组，且哮喘症状评分明显低于治疗前及对照组，差异均有统计学意义（P〈0.05）。对照组治疗前后各项指标比较差异均无统计学意义（P〉0.05）。结论：白三烯受体拮抗剂能够使吸烟哮喘患者的病情控制得到改善，可能是治疗吸烟哮喘患者的一种有效药物。

Impact of Leukotriene Receptor Antagonist on the Disease Control of Smoking Asthmatic Patients

Objective：To investigate the impact of leukotriene receptor antagonist on the disease control of smoking asthmatic patients.Method：110 smoking asthmatic patients in the outpatient clinic from March 2013 to December 2013 were selected.They were randomly divided into the control group for 54 cases and the treatment group for 56 cases according to the random number table method.The control group was treated with inhaled corticosteroid（budesonide）, and inhaledβ2 agonist when necessary.The treatment group was treated with montelukast sodium for 4 weeks on the basis of the control group.Asthma Control Test（ACT）score,asthma-symptom score and morning and night PEF were compared between the two groups before and after treatment.Result：The ACT score,morning and night PEF%pred of the treatment group after treatment were significantly higher than before treatment and the control group,asthma-symptom score after treatment was significantly lower than before treatment and the control group,the differences were statistically significant （P〈0.05）.In the control group,the indicators before and after treatment comparison difference had no statistical significance（P〉0.05）.Conclusion：Leukotriene receptor antagonist can improve the control of disease,may be an effective drug in the treatment of smoking asthmatic patients.